Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 14/20 | 0.96 |
| ▸ | BCHE | P06276 | 14/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL28459531 | 1.00 | BCHE (0.96) | BCHEACHE | |
| Iodide SCHEMBL30187207 | 1.00 | BCHE (0.96) | BCHEACHE | |
| SCHEMBL3606932 | 0.98 | BCHE (1.00) | BCHEACHE | |
| SCHEMBL3603725 | 0.98 | BCHE (1.00) | BCHEACHE | |
| SCHEMBL14951076 | 0.98 | BCHE (1.00) | BCHEACHE | |
| SCHEMBL4887020 | 0.98 | BCHE (1.00) | BCHEACHE | |
| SCHEMBL3588425 | 0.98 | BCHE (1.00) | BCHEACHE | |
| SCHEMBL3604422 | 0.98 | BCHE (1.00) | BCHEACHE | |
| SCHEMBL3596114 | 0.98 | BCHE (1.00) | BCHEACHE | |
| Bromide SCHEMBL4891809 | 0.96 | BCHE (1.00) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | WASHINGTON UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | WASHINGTON UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| US-20190298841-A1 | Nucleic Acid Complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2019-10-03 | — | — | US | disclosed |
| US-10350299-B2 | Nucleic acid complexes | PROCARTA BIOSYSTEMS LTD. (GB) | 2019-07-16 | — | — | US | disclosed |
| US-20170340745-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD. (GB) | 2017-11-30 | — | — | US | disclosed |
| US-9669101-B2 | Nucleic acid complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2017-06-06 | — | — | US | disclosed |
| US-9550991-B2 | Transcription factor decoys | PROCARTA BIOSYSTEMS LTD. (GB) | 2017-01-24 | — | — | US | disclosed |
| EP-2552455-B1 | TRANSCRIPTION FACTOR DECOYS | PROCARTA BIOSYSTEMS LTD (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-20150196652-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2015-07-16 | — | — | US | disclosed |
| US-9024005-B2 | Nucleic acid complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20140274800-A1 | TRANSCRIPTION FACTOR DECOYS FOR THE TREATMENT AND PREVENTION OF INFECTIONS CAUSED BY BACTERIA INCLUDING CLOSTRIDIUM DIFFICILE | PROCARTA BIOSYSTEMS LTD. (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20130252881-A1 | Transcription Factor Decoys | PROCARTA BIOSYSTEMS LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130059775-A1 | Nucleic Acid Complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2013-03-07 | — | — | US | disclosed |
| EP-2533815-A1 | NUCLEIC ACID COMPLEXES | Procarta Biosystems Ltd (GB) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098829-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272449-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | ACHE 3265/4885BCHE 2678/4885 |
| US-10350299-B2 | Nucleic acid complexes | ZFR, SUB1, RELA | ACHE 4834/4885BCHE 4569/4885 |
| US-12247246-B2 | Identification of inhibitors of TcpC and TIR NADase activity | NADK, NAPRT, TIPARP | ACHE 3265/4885BCHE 2678/4885 |
| US-20170340745-A1 | NUCLEIC ACID COMPLEXES | ZFR, SUB1, RELA | ACHE 4834/4885BCHE 4569/4885 |
| US-20200283820-A1 | IDENTIFICATION OF INHIBITORS OF TCPC AND TIR NADase ACTIVITY | NADK, NAPRT, TIPARP | ACHE 3265/4885BCHE 2678/4885 |
| US-20190298841-A1 | Nucleic Acid Complexes | ZFR, SUB1, RELA | ACHE 4834/4885BCHE 4569/4885 |
| US-20150196652-A1 | NUCLEIC ACID COMPLEXES | ZFR, SUB1, RELA | ACHE 4834/4885BCHE 4569/4885 |
| US-20130059775-A1 | Nucleic Acid Complexes | ZFR, SUB1, RELA | ACHE 4834/4885BCHE 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.